Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesna for Prevention of Contrast-Induced Nephropathy
NCT00223548Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2002
- Countries
- 1
- Sponsor
- Ulm University
- Modality
- Small Molecules
- Drugs
- mesna
- Conditions
- contrast-induced nephropathy (CIN)
01
Overview
Phase 2, randomised trial of mesna in contrast-induced nephropathy (CIN) (2 arms), sponsored by Ulm University. Primary endpoint: Contrast-agent associated nephrotoxicity at 48 hours. Started Oct 2002; status: completed.
02
Design
2 arms- Study design
- Randomized
Mesna + Saline
Mesna (sodium 2-mercaptoethane sulfonate) + Sodium Chloride hydration
Saline Control
Sodium Chloride hydration alone
03
Who it enrols
Patients with stable chronic renal insufficiency (serum creatinine > 1.5 mg/dl) undergoing contrast media exposure. Excludes patients on dialysis, with acute renal failure, recent contrast exposure, or allergy to Mesna.
04
Endpoints
Primary
Contrast-agent associated nephrotoxicity
Secondary
Need for dialysis
Beyond the preview
Go deeper on NCT00223548.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223548.